These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 18671476)
1. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476 [TBL] [Abstract][Full Text] [Related]
2. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B; HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978 [TBL] [Abstract][Full Text] [Related]
3. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only? Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129 [TBL] [Abstract][Full Text] [Related]
4. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465 [TBL] [Abstract][Full Text] [Related]
5. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE; HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008 [TBL] [Abstract][Full Text] [Related]
6. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study. Elion R; Cohen C; DeJesus E; Redfield R; Gathe J; Hsu R; Yau L; Ross L; Ha B; Lanier RE; Scott T; HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898 [TBL] [Abstract][Full Text] [Related]
7. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610 [TBL] [Abstract][Full Text] [Related]
8. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS; J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763 [TBL] [Abstract][Full Text] [Related]
9. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316 [TBL] [Abstract][Full Text] [Related]
10. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Stürmer M; Staszewski S; Doerr HW Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153 [TBL] [Abstract][Full Text] [Related]
11. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
12. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results. Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne. de Truchis P; Force G; Welker Y; Mechali D; Pulik M; Chemlal K; Rouveix E; Devidas A; Praindhui D; Mamet JP; J Acquir Immune Defic Syndr; 2002 Oct; 31(2):178-82. PubMed ID: 12394796 [TBL] [Abstract][Full Text] [Related]
14. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. Khanlou H; Yeh V; Guyer B; Farthing C AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380 [TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS; AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866 [TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962 [TBL] [Abstract][Full Text] [Related]
17. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036 [TBL] [Abstract][Full Text] [Related]
18. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660 [TBL] [Abstract][Full Text] [Related]
19. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B; AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238 [TBL] [Abstract][Full Text] [Related]
20. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]